Clinical trial · Observational
SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization
Single-Photon Emission Computed Tomography (SPECT) Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization (SEEtoTREAT)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators will study SPECT imaging of radiopharmaceutical therapies given as standard of care or as part of other compatible research protocols. The goal is to validate the quantitative SPECT image reconstruction methods developed in this proposal, and to investigate the relation between dosimetry calculated from SPECT images and the outcomes. Patients will be recruited for SPECT/CT imaging during treatment. This is an observational study no additional new drugs or activities will be administrated. The investigators will perform SPECT imaging on a total of 80 patients (\~20 each from year 2 to year 5). Each participant will be imaged 3 times after the first and last cycles of planned radiopharmaceutical therapy.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Cancer | Malignant Neoplasm | CURATED_BROADER | 0.78 |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 177Lu-DOTATATE | Radiation | — | UNRESOLVED |
| 177Lu-PSMA-617 | Radiation | — | UNRESOLVED |
| Radium-223 | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Cohort A
- description
- Patients with advanced prostate cancer planning to undergo treatment with Radium-223
- interventionNames
- Radiation: Radium-223
- label
- Cohort B
- description
- Patients with advanced cancer undergoing treatment with 177Lu-DOTATATE or 177Lu-PSMA-617
- interventionNames
- Radiation: 177Lu-DOTATATE
- Radiation: 177Lu-PSMA-617
Primary outcomes (1)
- measure
- Mean absorbed dose to normal organs compared using different quantitative methods
- timeFrame
- 48 months
- description
- The mean absorbed dose to normal organs (e.g. kidney) will be calculated for each patient and compared using different quantitative reconstruction methods for SPECT imaging.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: * Cohort A: Patients with advanced prostate cancer planning to undergo treatment with Radium-223 * Cohort B: Patients with advanced cancer undergoing treatment with 177Lu-DOTATATE or 177Lu-PSMA-617 \*\*Eligible patients may be planning to undergo these treatments as part of standard of care or as part of another research protocol * Age \> 18 years * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 * Histologic confirmation of malignancy Exclusion Criteria: * Patient is participating in another research protocol that does not allow participation in this imaging protocol or that has schedule of procedures that would not be compatible with this protocol. * Patient unable to tolerate SPECT scan time, scan frequency, or position.
References
Publications (0)
Data not yet available